Clinical Trial Detail

NCT ID NCT01548807
Title Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements no
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

prostate adenocarcinoma

Therapies

Everolimus

Age Groups: adult

No variant requirements are available.